Top Story

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma

Ipilimumab plus T-VEC demonstrates improved outcomes in melanoma
April 25, 2015

NEW YORK — Igor Puzanov, MD, MSCI, FACP, director of clinical melanoma research at Vanderbilt University, presents data from patients with melanoma who were treated with a combination of ipilimumab and talimogene laherparepvec, or T-VEC, at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.

“We found that the combination was not only safe, but it was more efficacious than expected for either single-agent T-VEC or single-agent ipilimumab, with a response rate of up to 53%, most of them durable,” Puzanov told HemOnc Today.

Meeting News Coverage

Durable response to T-VEC, GM-CSF linked to longer OS

April 25, 2015
NEW YORK — Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene laherparepvec or…
Meeting News Coverage

Algorithm predicts HCC in patients with cirrhosis

April 25, 2015
VIENNA — A new algorithm accurately predicted hepatocellular carcinoma among a cohort of patients with cirrhosis, according to a study presented at the 2015…
Cover StoryPublication Exclusive

Expansion of ‘Right to Try’ legislation raises ethical, safety concerns

HemOnc Today, April 25, 2015
Early access to experimental drugs has historically been reserved for patients enrolled on clinical trials.In 2009, the FDA revamped its 1980’s expanded access program…
Hemant Murthy, MD In PracticePublication Exclusive

State of the science: High-priority transplant trials for nonmalignant disease

HemOnc Today, April 25, 2015
Hemant Murthy, MD; William Wood, MD
Last June, we launched a series of columns in HemOnc Today intended to discuss high-priority proposals that emerged from the 2014 Blood and Marrow Transplant Clinical…
More News Headlines »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Registry data reconfirm the role of high-dose IL-2 in melanoma

VIDEO: Registry data reconfirm the role of high-dose IL-2 in melanoma

April 24, 2015
NEW YORK — Howard L. Kaufman, MD, FACP, associate director for clinical science at the Rutgers Cancer Institute…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan
morganatic-roan